| H型高血压临床研究进展 |
| |
| 引用本文： | 蒋晖.H型高血压临床研究进展[J].心血管病学进展,2012,33(4):491-493. |
| |
| 作者姓名： | 蒋晖 |
| |
| 作者单位： | 成都市第三人民医院心内科,四川成都,610031 |
| |
| 摘 要： | 高血压合并高同型半胱氨酸血症是发生脑卒中的重要危险因素,控制血压的同时降低同型半胱氨酸可减少脑卒中发生率。目前已知降低同型半胱氨酸最安全有效的方法是补充叶酸,早期关注同型半胱氨酸水平并检测基因型进行积极干预,将推动我国高血压个体化防治的发展,降低高危患者脑卒中风险。
|
| 关 键 词： | 高血压 同型半胱氨酸 叶酸 基因多态性 |
Clinical Research Progress in Hypertension with Hyperhomocysteinaemia |
| |
| JIANG Hui.Clinical Research Progress in Hypertension with Hyperhomocysteinaemia[J].Advances in Cardiovascular Diseases,2012,33(4):491-493. |
| |
| Authors: | JIANG Hui |
| |
| Institution: | (Department of Cardiology,The Third People’s Hospital of Chengdu,Chengdu 610031,Sichuan,China) |
| |
| Abstract: | Hypertension with hyperhomocysteinaemia is an important risk factor for stroke,so antihypertensive treatment with lowering homocystein can reduce stroke incidence.Folic acid supplementation has been demonstrated to lower plasma homocysteine levels safely and effectively.Homocysteine level and the genetic polymorphism of N5,10 methylenetetrahydrofolate reductase should be detected early,which can promote personalized medicine for hypertension and reduce stroke morbidity of high-risk patients. |
| |
| Keywords: | hypertension homocysteine folic acid genetic polymorphism |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
